Bin Su, Ph.D.
B_SU.jpg
 Title: Associate Professor
 Dept: Chemistry
 Office: SR 361
 Phone: 216-687-9219
 Email: B.SU@csuohio.edu
 Address: 2121 Euclid Ave. SR 361, Cleveland, OH 44115

Courses Taught

Publications


Faculty Only:
Update Profile
 

 
Research Keywords:
Drug development, Cancer, African trypanosomiasis, Synthetic medicinal chemistry, Pharmacology
 
Education:
Ph.D., Pharmacy, The Ohio State University, 2006
M.S., Pharmacy, The Ohio State University, 2005
M.S., Medicinal Chemistry, Peking University, 2002
B.S., Medicinal Chemistry, Beijing Medical University, 1996
 
Brief Bio:
Dr.Su graduated from the Ohio State University in Dr. Bob Brueggemeier's group, mainly focus on synthetic medicinal chemistry in breast cancer. Then he moved to City of Hope National Medical Center at LA to be further trained in cancer biology and molecular pharmacology related to translational researches by working with Dr. Shiuan Chen. He is well trained in synthetic medicinal chemistry, cancer biology, molecular endocrinology which enriched his expertise in drug design and development. He joined CSU at August 2009 and started his independent academic career. His research involves drug design, development and mechanism investigation.
 
Honors and Awards:
1999 Excellent Teacher Award, Beijing Medical University
2004    Donald T. WitiaK Graduate Student Award, College of Pharmacy, The Ohio State University                    
2005    Graduate Student-Postdoctoral Fellow Conference Award,
            Gordon Research Conference on Hormone Action in Development and Cancer
2009    Susan G. Komen postdoctoral fellowship (KG091280), declined due to new career as independent PI
2012 Faculty Merit Recognition Award of Research (CSU)
2013 Faculty Merit Recognition Award of Research (CSU)
2014 Faculty Merit Recognition Award of Research (CSU)
2014    Mentor of year, McNair scholar
 
Research Interests:
Dr.Su's research focuses on anti-cancer and anti-trypanosome drug development
1. Hsp27 inhibitor development. The expression of heat shock proteins (Hsp) is increased under lethal conditions, which is a typical response when cancer cells are stressed by chemotherapies. Hsp27, a small heat shock protein, shows a very tight correlation with anti-cancer drug resistance. Its over-expression enhances the survival of mammalian cells exposed to anti-cancer agents. Through biotinylated small molecular probe, affinity chromatography and proteomic approaches, our lab identified small molecule compound binding to Hsp27. Systematic ligand based optimization dramatically increased the cell proliferation inhibition and apoptosis inducing activities of the compounds. Drug candidates developed in this project have been tested by the Developmental Therapeutic Program at the National Cancer Institute for screening against 60 human cancer cell lines, representing leukemia, melanoma, and cancers of the lung, colon, CNS, ovary, renal, prostate, and breast. Our lab currently further optimizes the drug candidates to improve the ADME profile.
2. Selective tubulin inhibitors for the treatment of African trypanosomiasis. By collaborating with Dr. Bibo Li at BGES, we screened the small molecule compound library generated in our lab with T.brucei which is the parasite causing African sleep disease. Interestingly, we identified several lead compounds that selectively inhibited the parasite growth, and did not affect the mammalian cell proliferation. These compounds selectively interfere with parasite tubulin, and do not block the mammalian tubulin function. There is a great potential to develop cheap, easy make drug candidates for the treatment of the parasite disease.  
3. Lead optimization of HMBA, a cell differentiation agent. Hexamethylene bisacetamide (HMBA) is an agent showing promising anti-cancer activities. It has been investigated at national cancer institute in phase II clinical trial for cancer treatment. However, the dose related toxicity limited the further drug development. The compound exhibited its anti-cancer activity at micro mole range in the in vitro assays. It is critical to develop more potent analogs which will show lower toxicity. Dr. Monica Montano at CWRU pharmacology collaborates with us to optimize this compound. So far, about 40 new analogs have been developed. Very fortunately, we identified one derivative is 2500 times more active than the parental HMBA. We focus on the molecular targets identification of HMBA and its analogs currently.
 
Teaching Areas:
Pharmacology, biochemistry, bioorganic chemistry, drug discovery
 
Professional Affiliations:
Member of American Chemical Society
Member of American Association of Pharmaceutical Scientists
 
Professional Experience:
Conference Organizer for The 39th Mid-Atlantic Graduate Student Symposium in Medicinal Chemistry (MAGSS), June18-20, 2006, The Ohio State University, Columbus, OH
 
University Service:
member of undergraduate committee (Chemistry)
 
Professional Service:
Dr. Su is a reviewer on a routine basis for seven journals including Journal of medicinal chemistry, European Journal of medicinal chemistry, ChemMedChem, Medicinal chemistry communication, Current medicinal chemistry, Cancer epidemiology, Tumor biology.
Dr.Su is also an Editorial board member for Journal of cancer science and therapy.
 
Research Grants:
Ongoing Research Support

1.Drug development of orally active anti- trypanosomiasis agents
(Bin Su, PI) 01/15/2013-12/31/2015
Funding Agency: NIAID
Type: 1R15AI103889-01

2.MRI: Acquisition of an NMR Spectrometer (XueLong Sun, PI)   09/01/2011-08/31/2014
NSF
With this award from the Major Research Instrumentation (MRI) Program, Professor Xue-Long Sun from Cleveland State University and colleagues Bin Su, John Masnovi, and Nolan Holland will acquire a 400 MHz NMR spectrometer.

3.Startup research grant ( Bin Su, PI) 09/01/2009-08/30/2013
Cleveland State University
Anti- cancer drug development

Completed grants:

4.Scott Hamilton CARES initiative (Sergei vatolin, PI) 01/01/2012-12/30/2012
Title: Development of a Lead Non-Nucleoside DNA Methyltransferase Inhibitor for Use in   Hematological Malignancies
Agency: Cleveland Clinic
Role: Co-PI
5.Faculty Research Development grant  (Bin Su, PI)       07/01/2011-06/30/2012
Cleveland State University
Discovery of Dual PDE-5 and Tubulin inhibitors as anti-cancer agents
6.Summer undergraduate student research 2012 summer
Anti-breast cancer drug screening with 3D spheroid tumor assays